These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12632246)

  • 21. Brain serotonin2 receptors in major depression: a positron emission tomography study.
    Yatham LN; Liddle PF; Shiah IS; Scarrow G; Lam RW; Adam MJ; Zis AP; Ruth TJ
    Arch Gen Psychiatry; 2000 Sep; 57(9):850-8. PubMed ID: 10986548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
    Meyer JH; Wilson AA; Ginovart N; Goulding V; Hussey D; Hood K; Houle S
    Am J Psychiatry; 2001 Nov; 158(11):1843-9. PubMed ID: 11691690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-HT(1A) receptor binding changes in patients with major depressive disorder before and after antidepressant treatment: a pilot [¹⁸F]MPPF positron emission tomography study.
    Lothe A; Saoud M; Bouvard S; Redouté J; Lerond J; Ryvlin P
    Psychiatry Res; 2012 Jul; 203(1):103-4. PubMed ID: 22863653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia.
    Verhoeff NP; Meyer JH; Kecojevic A; Hussey D; Lewis R; Tauscher J; Zipursky RB; Kapur S
    Psychiatry Res; 2000 Oct; 99(3):123-35. PubMed ID: 11068194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic mechanism of antidepressant action in depressed patients.
    Willner P; Hale AS; Argyropoulos S
    J Affect Disord; 2005 May; 86(1):37-45. PubMed ID: 15820269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors.
    Massou JM; Trichard C; Attar-Levy D; Feline A; Corruble E; Beaufils B; Martinot JL
    Psychopharmacology (Berl); 1997 Sep; 133(1):99-101. PubMed ID: 9335087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.
    Brody AL; Saxena S; Silverman DH; Alborzian S; Fairbanks LA; Phelps ME; Huang SC; Wu HM; Maidment K; Baxter LR
    Psychiatry Res; 1999 Oct; 91(3):127-39. PubMed ID: 10641577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine.
    Munno D; Sterpone S; Fania S; Cappellin F; Mengozzi G; Saroldi M; Bechon E; Zullo G
    Panminerva Med; 2013 Dec; 55(4):377-84. PubMed ID: 24434345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists.
    Glennon RA; Metwally K; Dukat M; Ismaiel AM; De los Angeles J; Herndon J; Teitler M; Khorana N
    Curr Top Med Chem; 2002 Jun; 2(6):539-58. PubMed ID: 12052193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.
    Parsey RV; Oquendo MA; Ogden RT; Olvet DM; Simpson N; Huang YY; Van Heertum RL; Arango V; Mann JJ
    Biol Psychiatry; 2006 Jan; 59(2):106-13. PubMed ID: 16154547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.
    Jha MK; Rush AJ; Trivedi MH
    Am J Psychiatry; 2018 Dec; 175(12):1176-1184. PubMed ID: 30501420
    [No Abstract]   [Full Text] [Related]  

  • 34. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence.
    Meyer JH; Wilson AA; Sagrati S; Miler L; Rusjan P; Bloomfield PM; Clark M; Sacher J; Voineskos AN; Houle S
    Arch Gen Psychiatry; 2009 Dec; 66(12):1304-12. PubMed ID: 19996035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.
    Milak MS; Parsey RV; Lee L; Oquendo MA; Olvet DM; Eipper F; Malone K; Mann JJ
    Psychiatry Res; 2009 Jul; 173(1):63-70. PubMed ID: 19446443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
    Hodé Y; Benyamina A; Arbus C; Reimold M
    Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain Serotonin Release Is Reduced in Patients With Depression: A [
    Erritzoe D; Godlewska BR; Rizzo G; Searle GE; Agnorelli C; Lewis Y; Ashok AH; Colasanti A; Boura I; Farrell C; Parfitt H; Howes O; Passchier J; Gunn RN; Politis M; Nutt DJ; Cowen PJ; Knudsen GM; Rabiner EA
    Biol Psychiatry; 2023 Jun; 93(12):1089-1098. PubMed ID: 36635177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Erritzoe D; Rasmussen H; Kristiansen KT; Frokjaer VG; Haugbol S; Pinborg L; Baaré W; Svarer C; Madsen J; Lublin H; Knudsen GM; Glenthoj BY
    Neuropsychopharmacology; 2008 Sep; 33(10):2435-41. PubMed ID: 18288096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.